---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005258"
form_type: "8-K"
ticker: null
cik: "0001839133"
company_name: "IR-Med, Inc."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:32:33.904120+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IR-Med raises $43,619 from director-led private placement; CEO Ran Ziskind resigns

## Summary
- Gross proceeds of $43,619 from sale of 14,070,644 shares at $0.0031 and warrants for 7,035,322 shares at $0.03.
- Directors Oded Bashan, Yaniv Cohen, Yechiel Even, Ron Mayron, and Aharon Klein participated in the offering.
- CEO Ran Ziskind resigned effective February 3, 2026, citing disagreements on strategic direction and management.
- Warrants have a 5-year term and are immediately exercisable at $0.03 per share.

## SEC filing metadata
- accession: 0001493152-26-005258
- form_type: 8-K
- cik: 0001839133
- company_name: IR-Med, Inc.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1839133/000149315226005258/0001493152-26-005258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1839133/000149315226005258/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005258
- JSON: https://secwatch.observer/filing/0001493152-26-005258.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005258.txt

## Key facts
- Material Agreements
  IR-Med, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of $43,619 (effective 2026-02-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: aggregate gross proceeds of $43,619
  - Effective: 2026-02-04
  source text: On February 4, 2026, IR-Med, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement offering (the “Offering”), an aggregate of 14,070,644 shares of the Company’s common stock, par value $0.001 per share, (the “Common Stock”), at a per share price of $0.0031 and a warrant to purchase up to an additional 7,035,322 shares of Common Stock (the “Warrants”) at a per share exercise price of $0.03 (the “Exercise Price”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1839133/000149315226005258/0001493152-26-005258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.